Evaluation of systemic amyloidosis by scintigraphy with 123I-labeled serum amyloid P component.
about
Apolipoprotein AI mutation Arg-60 causes autosomal dominant amyloidosisUpdate on treatment of light chain amyloidosisEarly detection of sensorineural hearing loss in Muckle-Wells-syndromeProteolytic cleavage of Ser52Pro variant transthyretin triggers its amyloid fibrillogenesisStop chronic kidney disease progression: Time is approachingImaging linear birefringence and dichroism in cerebral amyloid pathologiesBinding of pentraxins to different nuclear structures: C-reactive protein binds to small nuclear ribonucleoprotein particles, serum amyloid P component binds to chromatin and nucleoliPentraxins: structure, function, and role in inflammationMedical imaging.Amyloidogenicity and clinical phenotype associated with five novel mutations in apolipoprotein A-I.Laryngeal amyloidosis: localized versus systemic disease and update on diagnosis and therapy.Amyloidosis and the respiratory tractIsolation and characterization of pharmaceutical grade human pentraxins, serum amyloid P component and C-reactive protein, for clinical use.Metabolic and scintigraphic studies of radioiodinated human C-reactive protein in health and disease.Thoracic amyloidomas: Two case reports of an evasive diagnosisThe pentraxins, C-reactive protein and serum amyloid P component, are cleared and catabolized by hepatocytes in vivo.Effect of hemodialysis membranes on beta 2-microglobulin amyloidosis.Guideline of transthyretin-related hereditary amyloidosis for clinicians.Senile systemic amyloidosis: clinical features at presentation and outcome.AL amyloid imaging and therapy with a monoclonal antibody to a cryptic epitope on amyloid fibrils.Proteomic analysis of highly prevalent amyloid A amyloidosis endemic to endangered island foxesOld men and thickened heartsThe liver in systemic amyloidosis: insights from 123I serum amyloid P component scintigraphy in 484 patients.A critical analysis of postulated pathogenetic mechanisms in amyloidogenesis.Long term results of heart transplantation in patients with amyloid heart disease.A novel transthyretin variant p.H110D (H90D) as a cause of familial amyloid polyneuropathy in a large Irish kindred.Human serum amyloid P component is an invariant constituent of amyloid deposits and has a uniquely homogeneous glycostructure.Reactive amyloidosis.Radioimaging of light chain amyloid with a fibril-reactive monoclonal antibodyMetabolic studies of radioiodinated serum amyloid P component in normal subjects and patients with systemic amyloidosis.Induction in mice of human light-chain-associated amyloidosis.Imaging Findings and Literature Review of (18)F-FDG PET/CT in Primary Systemic AL Amyloidosis.18F-Florbetapir Binds Specifically to Myocardial Light Chain and Transthyretin Amyloid Deposits: Autoradiography Study.Prognostic Value of Late Gadolinium Enhancement Cardiovascular Magnetic Resonance in Cardiac Amyloidosis.Updates in cardiac amyloidosis: a review.D25V apolipoprotein C-III variant causes dominant hereditary systemic amyloidosis and confers cardiovascular protective lipoprotein profile.Drug Insight: emerging therapies for amyloidosis.Comparative evaluation of p5+14 with SAP and peptide p5 by dual-energy SPECT imaging of mice with AA amyloidosis.Intestinal pseudo-obstruction due to amyloidosis of the colon in association with an intestinal plasmacytoma.Amyloidosis and the lung.
P2860
Q24564368-481B525E-BB97-4257-85F7-D44E3C558421Q26829735-930A78E2-EC7E-4571-8D62-7AEAE3A8CA79Q27303524-30A40846-B6E4-40F1-BBD2-77D75CF41E22Q27681502-8A49534E-0046-4F94-B78F-E5A8265574B9Q28078020-B098DECC-4262-4BA9-A93D-281E356BCD66Q28387800-70F33ECF-BFB3-49CF-9006-F37046F48965Q28610085-F9B75CBD-3422-488D-84B8-099EDC48677AQ28676262-56824FD8-CB47-4C52-A7A8-40076552B408Q30493407-CB07B6D2-B699-4680-AF20-18178AD9AE94Q31029305-2B5E3952-1F7E-4D5D-88E9-C45AA8AAB336Q31117033-DBE22FD6-A641-44ED-9D18-18BEB713F5A8Q33598909-66672CD1-36FB-4C9C-A16E-7672C277A542Q33796862-083FC797-FA93-4458-A10B-5419D8ABC4F5Q33895058-CC89934D-C7F0-4A69-A5D6-3F31E4525ED8Q33908070-1D880DDE-99EA-4556-BD50-78F39CB1D3C8Q34188358-09F9FDBD-9C83-459E-9980-FF8903EC29CCQ34193006-D949B538-3507-4754-8ED4-9385AB5387C1Q34328734-6AE44F5B-EC05-476B-92DB-3FBE37AA706EQ34340740-7AFDA456-52B2-48B1-84A7-3F5AEEA55A28Q34541038-DD855D4C-2E74-420A-A58C-DBE1C51F7BC7Q34579925-15626DFF-3F6C-4110-9859-E1DEE26D4055Q34617377-A7F7F527-6A50-4C7B-BA70-E47B4727797AQ35350650-810AD9FA-C3CD-430B-AA39-9754CF735313Q35353067-9A875077-DCF8-4CE0-B302-45CFACBF2D08Q35378115-60B849C2-3CDB-438A-86F4-D0807DD4EE64Q35456927-DECEA6D8-CB39-4E6E-9204-0E0E7E089C54Q35501399-11A1A7C3-BE25-475A-A00B-3459B1887C5FQ35627897-A3F5C121-7C56-4174-810F-DE82D113B985Q35785799-314A3AEF-2E58-478B-9756-B32CE07197FAQ35817146-A766E9A9-3C8E-443A-8130-CC5254EFE794Q35830611-D80592C8-B8C5-4481-A36D-AB195795FB18Q35941115-6EEEBDB9-C4BE-44D0-8705-3FB5EC47260BQ35949385-36D7C3A4-C42D-4872-B960-A2FB5B97C5FBQ36165179-9F19687E-DB1D-446B-B6F2-0D1CC260F31BQ36366356-FE782BBD-8321-42FC-A25E-660BB9FF8CD6Q36528525-CB298FCE-EE07-4CFC-8453-9D9BE0EA0D49Q36577160-DFBDBEEF-128B-4306-95A1-CA799D86F539Q36645348-0598F36B-BF66-4E0E-B759-C83CA1174409Q36682371-351523B8-ECDF-44C6-8D90-285C579A30C7Q36692876-2AEB8618-F97F-4F91-8067-5F0B19227CBD
P2860
Evaluation of systemic amyloidosis by scintigraphy with 123I-labeled serum amyloid P component.
description
1990 nî lūn-bûn
@nan
1990 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
1990 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
1990年の論文
@ja
1990年論文
@yue
1990年論文
@zh-hant
1990年論文
@zh-hk
1990年論文
@zh-mo
1990年論文
@zh-tw
1990年论文
@wuu
name
Evaluation of systemic amyloid ...... led serum amyloid P component.
@ast
Evaluation of systemic amyloid ...... led serum amyloid P component.
@en
Evaluation of systemic amyloid ...... led serum amyloid P component.
@nl
type
label
Evaluation of systemic amyloid ...... led serum amyloid P component.
@ast
Evaluation of systemic amyloid ...... led serum amyloid P component.
@en
Evaluation of systemic amyloid ...... led serum amyloid P component.
@nl
prefLabel
Evaluation of systemic amyloid ...... led serum amyloid P component.
@ast
Evaluation of systemic amyloid ...... led serum amyloid P component.
@en
Evaluation of systemic amyloid ...... led serum amyloid P component.
@nl
P1476
Evaluation of systemic amyloid ...... led serum amyloid P component.
@en
P2093
Hawkins PN
Lavender JP
P304
P356
10.1056/NEJM199008233230803
P407
P50
P577
1990-08-01T00:00:00Z